title: TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS.
abstract: HIV infection remains a major global public health problem, in part because of the ability of the virus to elude antiretroviral therapies. Most conventional drugs were designed to directly target virus-encoded mechanisms. However, there is increasing appreciation that certain host-encoded molecules are comparably important for the viral life cycle and could therefore represent potential antiviral targets. Prominent among these is TSG101, a cytoplasmic molecule that is "hijacked" by HIV and used to facilitate viral budding and release. In our present report, we demonstrate thatTSG101 is uniquely exposed on the surface of HIV-infected cells and is available to antibody-based therapies. We also characterize the development of a monoclonal antibody, CB8-2, which reduces virus production from infected cells. These studies demonstrate the potential of TSG101-directed antibodies to combat HIV/AIDS.
authors: Leyla
authors: L
authors: Diaz
authors: Hanwen
authors: H
authors: Mao
authors: Yu
authors: Y
authors: Zhou
authors: Manu
authors: M
authors: Kohli
authors: Josephine
authors: J
authors: Cassella
authors: David
authors: D
authors: Santos
authors: Zena
authors: Z
authors: Fesseha
authors: Ke
authors: K
authors: Weng
authors: Hanson
authors: H
authors: Chen
authors: Douty
authors: D
authors: Bamba
authors: James D
authors: JD
authors: Marks
authors: Michael
authors: M
authors: Goldblatt
authors: Michael
authors: M
authors: Kinch